Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 5Mycoses 5Leukemia, Myeloid, Acute 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia 3Infections 3Neutropenia 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Torulopsis 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Stem Cell Transplant Complications 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Sezary Syndrome 1Seminoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1

Interventions

zanubrutinib 3tislelizumab 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1Influenza Vaccines 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
B-cell Malignancies × Fluconazole × Clear all
NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡